Literature DB >> 19065750

Sorafenib in advanced hepatocellular carcinoma.

Daniel H Palmer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19065750

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  37 in total

Review 1.  Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing?

Authors:  Tarek Magdy; Brian T Burmeister; Paul W Burridge
Journal:  Pharmacol Ther       Date:  2016-09-05       Impact factor: 12.310

2.  Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer.

Authors:  Dai Liu; Guangfu Li; Diego M Avella; Eric T Kimchi; Jussuf T Kaifi; Mark P Rubinstein; E Ramsay Camp; Don C Rockey; Todd D Schell; Kevin F Staveley-O'Carroll
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

3.  Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.

Authors:  Chin-Shiu Huang; Shih-Chieh Lyu; Miao-Lin Hu
Journal:  Invest New Drugs       Date:  2011-08-09       Impact factor: 3.850

4.  A new classification for hepatocellular carcinoma with hepatic vein tumor thrombus.

Authors:  Zhen-Hua Chen; Kang Wang; Xiu-Ping Zhang; Jing-Kai Feng; Zong-Tao Chai; Wei-Xing Guo; Jie Shi; Meng-Chao Wu; Wan Yee Lau; Shu-Qun Cheng
Journal:  Hepatobiliary Surg Nutr       Date:  2020-12       Impact factor: 7.293

5.  A Novel Vaccine Targeting Glypican-3 as a Treatment for Hepatocellular Carcinoma.

Authors:  Qunfeng Wu; Liya Pi; Thu Le Trinh; Chaohui Zuo; Man Xia; Yu Jiao; Zhouhua Hou; Sung Jo; William Puszyk; Kien Pham; David R Nelson; Keith Robertson; David Ostrov; Pranela Rameshwar; Chang Qing Xia; Chen Liu
Journal:  Mol Ther       Date:  2017-08-10       Impact factor: 11.454

6.  Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.

Authors:  Alok R Singh; Shweta Joshi; Adam M Burgoyne; Jason K Sicklick; Sadakatsu Ikeda; Yuko Kono; Joseph R Garlich; Guillermo A Morales; Donald L Durden
Journal:  Mol Cancer Ther       Date:  2016-08-05       Impact factor: 6.261

7.  LncRNA PCNAP1 Promotes Hepatoma Cell Proliferation through Targeting miR-340-5p and is Associated with Patient Survival.

Authors:  Miao He; Lingjing Hu; Ping Bai; Tingting Guo; Nan Liu; Fei Feng; Jin Zhang
Journal:  J Oncol       Date:  2021-04-28       Impact factor: 4.375

8.  Functional analysis of microRNAs in human hepatocellular cancer stem cells.

Authors:  Fanyin Meng; Shannon S Glaser; Heather Francis; Sharon DeMorrow; Yuyan Han; Jenna D Passarini; Allison Stokes; John P Cleary; Xiuping Liu; Julie Venter; Preetham Kumar; Sally Priester; Levi Hubble; Dustin Staloch; Jay Sharma; Chang-Gong Liu; Gianfranco Alpini
Journal:  J Cell Mol Med       Date:  2012-01       Impact factor: 5.310

9.  Increased miR-221 expression in hepatocellular carcinoma tissues and its role in enhancing cell growth and inhibiting apoptosis in vitro.

Authors:  Minhua Rong; Gang Chen; Yiwu Dang
Journal:  BMC Cancer       Date:  2013-01-16       Impact factor: 4.430

10.  Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.

Authors:  Qiang-Bo Zhang; Hui-Chuan Sun; Ke-Zhi Zhang; Qing-An Jia; Yang Bu; Miao Wang; Zong-Tao Chai; Quan-Bao Zhang; Wen-Quan Wang; Ling-Qun Kong; Xiao-dong Zhu; Lu Lu; Wei-Zhong Wu; Lu Wang; Zhao-You Tang
Journal:  PLoS One       Date:  2013-02-08       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.